Anti-endotoxin mechanism of the KW4 peptide in inflammation in RAW 264.7 cells induced by LTA and drug-resistant Staphylococcus aureus 1630
Drug-resistant microorganism infections cause serious disease and can lead to mortality and morbidity. In particular, Staphylococcus aureus induces pyrogenic and toxigenic infections, and drug-resistance occurs rapidly. Multidrug-resistant S. aureus , such as methicillin-resistant S. aureus and meth...
Gespeichert in:
Veröffentlicht in: | Amino acids 2018-04, Vol.50 (3-4), p.363-372 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Drug-resistant microorganism infections cause serious disease and can lead to mortality and morbidity. In particular,
Staphylococcus aureus
induces pyrogenic and toxigenic infections, and drug-resistance occurs rapidly. Multidrug-resistant
S. aureus
, such as methicillin-resistant
S. aureus
and methicillin-sensitive
S. aureus
, can also cause immunodeficiency and immune deficiency syndrome from lipoteichoic acid. However, antimicrobial peptides, such as KW4, have strong antimicrobial activity, low cytotoxicity, and high neutralization activity against endotoxin substances from Gram-negative bacteria. The objective of this study was to use a synthetic KW4 antimicrobial peptide to evaluate the inhibition of drug-resistance development, antimicrobial activity, and neutralizing activity in
S. aureus
Gram-positive bacteria. The KW4 peptide showed strong antimicrobial activity against drug-resistant
S. aureus
strains and significantly increased the anti-neutralizing activity of lipoteichoic acid in
S. aureus
1630 drug-resistant bacteria. In addition,
S. aureus
ATCC 29213 did not develop resistance to KW4 as with other antibiotic drugs. These results suggest that the KW4 peptide is an effective antibiotic and anti-neutralizing agent against multidrug-resistant
S. aureus
strains. |
---|---|
ISSN: | 0939-4451 1438-2199 |
DOI: | 10.1007/s00726-017-2518-y |